Merck & Co. shares reached a fresh 52-week high after Phase 3 INTerpath-001 results showed that Moderna’s personalized mRNA cancer vaccine intismeran autogene, or V940, combined with Keytruda significantly improved recurrence-free and distant metastasis-free survival in 1,137 patients with high-risk, completely resected Stage IIB-IV melanoma. Five-year Phase 2b follow-up showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death versus Keytruda alone, marking the first positive Phase 3 result for a personalized mRNA cancer vaccine. The results supported expectations for Merck’s pipeline and Keytruda subcutaneous conversion strategy, while CancerVax said they strengthened the scientific rationale for its preclinical, non-personalized, off-the-shelf LNP-mRNA cancer-vaccine platform. Moderna shares later fell 6.49% to $135.71 after surging more than 120% in one session and more than 150% over the prior week, according to the reports.